The WHO triggered its highest level of alert in the face of the outbreak of this disease which mainly affects men who have sex with other men.
Article written by
Published
Reading time : 1 min.
The European Commission has approved the extension of a vaccine from the pharmaceutical group Bavarian Nordic against the spread of monkeypox, the Danish laboratory announced on Monday July 25. The green light from Brussels comes as the WHO on Saturday triggered son highest level of alert in the face of the outbreak and after the endorsement, given by the European Medicines Agency (EMA) on Friday.
“This monkeypox approval is an example of good cooperation between Bavarian Nordic and European regulators, with a job extension normally taking between six to nine months”, welcomed the Danish manufacturer in a press release. The green light from the Commission is valid in all member countries of the European Union as well as in Iceland, Liechtenstein and Norway, specifies the group. This Imvanex vaccine, marketed as Jynneos in the United States, is the only licensed vaccine for the prevention of the disease.
There were more than 16,000 people infected worldwide at the end of last week, the majority of them in Europe. In most cases, the patients are men who have sex with men, relatively young, but the WHO has strongly warned against any stigmatization of the patients.